These Case-Based Roundtable article and video series explore recent perspectives on treatment strategies around clinical case profiles.
Later-Line Options for Patients With PSMA-Positive mCRPC
July 25th 2022This roundtable series evaluates radioligand therapy in patients with previously treated metastatic castration-resistant prostate cancer with positive prostate-specific membrane antigen, as discussed by participants at virtual live events.
DLBCL Management With Combination Therapy in the Relapsed/Refractory Setting
July 6th 2022This roundtable series assesses the use of antibody-drug conjugates plus chemoimmunotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma setting, as discussed by participants at virtual live events.
Chemotherapy Utilized in Pretreated Metastatic Castration-Resistant Prostate Cancer
June 15th 2022This roundtable series discusses when to use chemotherapy and best dosing practices in patients with metastatic castration-resistant prostate cancer after treatment with docetaxel, as discussed by participants at virtual live events.
Therapy With Bispecific Antibody for EGFR Exon 20 Insertion–Mutated NSCLC
April 27th 2022This roundtable series reviews the use of treatment targeting EGFR exon 20 insertion mutations in patients with locally advanced or metastatic non–small cell lung cancer, as discussed by participants at virtual live events.
Frontline and Subsequent Therapies for Chronic Lymphocytic Leukemia
April 1st 2022This roundtable series assesses the use of Bruton tyrosine kinase inhibition for patients with previously untreated or relapsed/refractory chronic lymphocytic leukemia, as discussed by participants at virtual live events.
JAK Inhibitor Therapy in the Myeloproliferative Neoplasm Population
March 18th 2022This roundtable series reflects on the management of patients with myeloproliferative neoplasms and JAK mutations, from biopsy and diagnosis to the use of JAK inhibition as treatment, as discussed by participants at virtual live events.
Using Anti-CD38 Monoclonal Antibodies as Treatment in Multiple Myeloma
January 7th 2022This roundtable series explores triplet and quadruplet combination therapies, including anti-CD38 monoclonal antibodies, with or without transplant in patients with multiple myeloma as discussed by participants at virtual live events.